Weiss Ratings restated their sell (e+) rating on shares of 908 Devices (NASDAQ:MASS – Free Report) in a research note issued to investors on Saturday morning,Weiss Ratings reports.
Other equities analysts have also issued reports about the stock. Stephens restated an “overweight” rating and set a $6.00 target price on shares of 908 Devices in a research report on Wednesday. Leerink Partners restated a “market perform” rating and issued a $4.00 price objective (down from $12.00) on shares of 908 Devices in a research note on Wednesday, November 13th. Stifel Nicolaus decreased their target price on shares of 908 Devices from $17.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Finally, Leerink Partnrs lowered 908 Devices from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 13th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $5.33.
Check Out Our Latest Stock Report on 908 Devices
908 Devices Trading Up 2.8 %
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in 908 Devices in the 3rd quarter valued at approximately $36,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of 908 Devices in the 3rd quarter valued at approximately $45,000. Drive Wealth Management LLC purchased a new stake in shares of 908 Devices in the third quarter valued at approximately $50,000. Townsquare Capital LLC acquired a new position in 908 Devices during the third quarter worth $50,000. Finally, 49 Wealth Management LLC raised its position in 908 Devices by 16.2% in the third quarter. 49 Wealth Management LLC now owns 31,099 shares of the company’s stock worth $108,000 after acquiring an additional 4,343 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.
About 908 Devices
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
Recommended Stories
- Five stocks we like better than 908 Devices
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Oilfield Leader SLB: An AI Name You Need to Know
- What is Forex and How Does it Work?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.